Search Preview
Diversion of Drug - DYNALABS
dynalabs.us888.396.2522 314.241.3962
.us > dynalabs.us
SEO audit: Content analysis
Language | Error! No language localisation is found. | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Title | Diversion of Drug - DYNALABS | ||||||||||||||||||||||||||||||||||||
Text / HTML ratio | 7 % | ||||||||||||||||||||||||||||||||||||
Frame | Excellent! The website does not use iFrame solutions. | ||||||||||||||||||||||||||||||||||||
Flash | Excellent! The website does not have any flash contents. | ||||||||||||||||||||||||||||||||||||
Keywords cloud | DYNALABS Services Drug Bulletin Tech drug Program Validation drugs • Process FDA testing DVx™ Customer Registration Diversion Pharmacies Product System | ||||||||||||||||||||||||||||||||||||
Keywords consistency |
|
||||||||||||||||||||||||||||||||||||
Headings |
|
||||||||||||||||||||||||||||||||||||
Images | We found 14 images on this web page. |
SEO Keywords (Single)
Keyword | Occurrence | Density |
---|---|---|
DYNALABS | 20 | 1.00 % |
Services | 8 | 0.40 % |
Drug | 8 | 0.40 % |
Bulletin | 7 | 0.35 % |
Tech | 7 | 0.35 % |
drug | 6 | 0.30 % |
Program | 6 | 0.30 % |
Validation | 6 | 0.30 % |
drugs | 5 | 0.25 % |
• | 5 | 0.25 % |
Process | 4 | 0.20 % |
FDA | 4 | 0.20 % |
testing | 4 | 0.20 % |
DVx™ | 4 | 0.20 % |
Customer | 4 | 0.20 % |
Registration | 4 | 0.20 % |
Diversion | 4 | 0.20 % |
Pharmacies | 3 | 0.15 % |
Product | 3 | 0.15 % |
System | 3 | 0.15 % |
SEO Keywords (Two Word)
Keyword | Occurrence | Density |
---|---|---|
Tech Bulletin | 7 | 0.35 % |
2018 Tech | 7 | 0.35 % |
Validation Program | 4 | 0.20 % |
of Drug | 4 | 0.20 % |
DYNALABS LLC | 3 | 0.15 % |
Diversion of | 3 | 0.15 % |
its testing | 2 | 0.10 % |
of its | 2 | 0.10 % |
size of | 2 | 0.10 % |
the size | 2 | 0.10 % |
doubles the | 2 | 0.10 % |
investment doubles | 2 | 0.10 % |
DYNALABS investment | 2 | 0.10 % |
of the | 2 | 0.10 % |
Testing for | 2 | 0.10 % |
drugs for | 2 | 0.10 % |
DYNALABS Announces | 2 | 0.10 % |
2017 DYNALABS | 2 | 0.10 % |
Entrepreneurial Success | 2 | 0.10 % |
drugs may | 2 | 0.10 % |
SEO Keywords (Three Word)
Keyword | Occurrence | Density | Possible Spam |
---|---|---|---|
2018 Tech Bulletin | 7 | 0.35 % | No |
Diversion of Drug | 3 | 0.15 % | No |
the size of | 2 | 0.10 % | No |
of its testing | 2 | 0.10 % | No |
Do Hospital Pharmacies | 2 | 0.10 % | No |
of Drug Diversion | 2 | 0.10 % | No |
Drug Diversion of | 2 | 0.10 % | No |
Services Lab Services | 2 | 0.10 % | No |
may be diluted | 2 | 0.10 % | No |
drugs may be | 2 | 0.10 % | No |
What We Do | 2 | 0.10 % | No |
its testing facility | 2 | 0.10 % | No |
size of its | 2 | 0.10 % | No |
Registration Account Registration | 2 | 0.10 % | No |
User Registration Account | 2 | 0.10 % | No |
doubles the size | 2 | 0.10 % | No |
investment doubles the | 2 | 0.10 % | No |
DYNALABS investment doubles | 2 | 0.10 % | No |
We Do Hospital | 2 | 0.10 % | No |
to be a | 1 | 0.05 % | No |
SEO Keywords (Four Word)
Keyword | Occurrence | Density | Possible Spam |
---|---|---|---|
size of its testing | 2 | 0.10 % | No |
Drug Diversion of Drug | 2 | 0.10 % | No |
investment doubles the size | 2 | 0.10 % | No |
doubles the size of | 2 | 0.10 % | No |
the size of its | 2 | 0.10 % | No |
of its testing facility | 2 | 0.10 % | No |
drugs may be diluted | 2 | 0.10 % | No |
What We Do Hospital | 2 | 0.10 % | No |
We Do Hospital Pharmacies | 2 | 0.10 % | No |
of Drug Diversion of | 2 | 0.10 % | No |
DYNALABS investment doubles the | 2 | 0.10 % | No |
User Registration Account Registration | 2 | 0.10 % | No |
therapeutic utilization Some hospitals | 1 | 0.05 % | No |
to track their staff | 1 | 0.05 % | No |
of drugs for a | 1 | 0.05 % | No |
drugs for a purpose | 1 | 0.05 % | No |
for a purpose other | 1 | 0.05 % | No |
to be a deterrent | 1 | 0.05 % | No |
a purpose other than | 1 | 0.05 % | No |
shown to be a | 1 | 0.05 % | No |
Internal links in - dynalabs.us
Products & Services - DYNALABS
Lab Services - DYNALABS
DVx™ On site Drug Verification - DYNALABS
Continuous Quality Improvement (CQI) - DYNALABS
Consulting Services - DYNALABS
Customer Improvement System - DYNALABS
Customer Production System - DYNALABS
Data Analytics - DYNALABS
Laboratory Services - DYNALABS
Test Services - DYNALABS
API (Active Pharmaceutical Ingredient ) list - DYNALABS
DVx™ Specifications - DYNALABS
DVx™ Validation Process - DYNALABS
DVx™ General FAQs - DYNALABS
On-site Managed Services - DYNALABS
Consulting - DYNALABS
Improvement Systems - DYNALABS
Production System - DYNALABS
Six Step Approach - DYNALABS
DYNALABS OOS Process - DYNALABS
Online Services - DYNALABS
Sample Submission - DYNALABS
Customer Service - DYNALABS
What We Do - DYNALABS
Hospital Pharmacies - DYNALABS
Stability of Drug - DYNALABS
Diversion of Drug - DYNALABS
In House Training - DYNALABS
Product Validation - DYNALABS
Drug Investigation - DYNALABS
Compounding Pharmacies - DYNALABS
People: Training Validation Program - DYNALABS
Materials: Vendor Qualification Program - DYNALABS
Equipment: Performance Validation Program - DYNALABS
Process: Process Validation Program - DYNALABS
Product: Product Validation Program - DYNALABS
Frequently Asked Questions - DYNALABS
Company - DYNALABS
Our Story - DYNALABS
Announcements - DYNALABS
Announcing a new National Accounts Manager, Christine Versichele. - DYNALABS
DYNALABS announces new Chief Technology Officer - DYNALABS
DYNALABS welcomes a new Principal Consultant - DYNALABS
DYNALABS embarks on $1.2 million expansion - DYNALABS
DYNALABS Announces a New Vice President of Sales - DYNALABS
DYNALABS announces Director of Quality & Regulatory Affairs - DYNALABS
DYNALABS Enhances Antimicrobial Effectiveness Testing for USP - DYNALABS
Potency Testing for Oxytocin - DYNALABS
DYNALABS Announces New President - DYNALABS
DYNALABS investment doubles the size of its testing facility - DYNALABS
Custom Packing Slip - DYNALABS
DYNALABS Receives ISO/IEC 17025 Accreditation - DYNALABS
DYNALABS investment doubles the size of its testing facility - DYNALABS
Enforcing FDA Labeling Policies - DYNALABS
Entrepreneurial Success Award - DYNALABS
Events - DYNALABS
Vision, Mission - DYNALABS
Leadership - DYNALABS
Partners and Alliances - DYNALABS
Investor Information - DYNALABS
Resources - DYNALABS
Webinars - DYNALABS
Blogs - DYNALABS
Industry News - DYNALABS
FDA to Remove APIs from list - DYNALABS
FDA Drug Shortages - DYNALABS
The Pharma Reports - DYNALABS
Careers - DYNALABS
Contact - DYNALABS
Working Towards 503B Certification - DYNALABS
DVx™ for On-site Drug Verification - DYNALABS
Partnering for 503B Compliance - DYNALABS
Terms Of Use - DYNALABS
Privacy Policy - DYNALABS
Customer Agreement - DYNALABS
Dynalabs.us Spined HTML
Diversion of Drug - DYNALABS 888.396.2522 314.241.3962 888.396.2522 • 314.241.3962 • info@dynalabs.us LOGIN User Registration Account Registration Menu Close Login User Registration Account Registration Products & Services Lab Services State-of-the-art tampering testing laboratory provides data you need to run your business. On Site Testing Less than 4 seconds to objectively verify drug identity and strength in your facility. CQI Program Use our expert knowledge of the pharmaceutical industry to help you grow your business. Continuous Quality Improvement (CQI) Consulting Services Customer Improvement System Customer Production System Data Analytics Laboratory Services Test Services Lab Services API (Active Pharmaceutical Ingredient ) list DVx™ On site Drug Verification DVx™ Specifications DVx™ Validation Process DVx™ General FAQs On-site Managed Services Consulting Improvement Systems Production System Six Step Approach DYNALABS OOS Process Online Services Sample Submission Customer Service What We DoHospital Pharmacies Stability of Drug Diversion of Drug In House Training Product Validation Drug Investigation Compounding Pharmacies People: Training Validation Program Materials: Vendor Qualification Program Equipment: Performance Validation Program Process: Process Validation Program Product: Product Validation Program Frequently Asked Questions CompanyOur Story Announcements Announcing a new National Accounts Manager, Christine Versichele. DYNALABS announces new Chief Technology Officer DYNALABS welcomes a new Principal Consultant DYNALABS embarks on $1.2 million expansion DYNALABS Announces a New Vice President of Sales DYNALABS announces Director of Quality & Regulatory Affairs DYNALABS LLC Named One of Inc. 5000 Fastest-Growing Private Companies in 2017 DYNALABS named to the 50 Fastest Growing Companies of 2017 DYNALABS Enhances Antimicrobial Effectiveness Testing for USP Potency Testing for Oxytocin DYNALABS Announces New President DYNALABS investment doubles the size of its testing facility Custom Packing Slip DYNALABS Receives ISO/IEC 17025 Accreditation Entrepreneurial Success SmallMerchantryof the Year 2016 DYNALABS investment doubles the size of its testing facility Enforcing FDA Labeling Policies Entrepreneurial Success Award Events Registrations and Awards Vision, Mission Leadership Partners and Alliances Investor Information ResourcesWebinars Blogs Industry News FDA to Remove APIs from list FDA Drug Shortages The Pharma Reports The Pharma Report | Sept 2018 Tech Bulletin | June 2018 Tech Bulletin | May 2018 Tech Bulletin | April 2018 Tech Bulletin | March 2018 Tech Bulletin | February 2018 Tech Bulletin | January 2018 Tech Bulletin | December 2017 Careers Contact < Home | What We Do | Hospital Pharmacies | Diversion of Drug Diversion of Drug NARCOTICS RETURN DEFINITION OF DRUG DIVERSION The use of drugs for a purpose other than intended therapeutic utilization. Some hospitals have issued protocol(s) to randomly test drug waste to track their staff routinely. Waste monitoring has shown to be a deterrent for drug diversion wideness healthcare employees. Examples – Expensive drugs may be diluted lanugo unelevated therapeutic levels to “save money” and narcotic drugs may be diluted to obtain drugs for personal/recreational use or sale. Where Diversion Happens: Point of Purchase, Patient- Specific Items, Multi-dose Vials or Bulk Items, High Cost Medication, Discrepancy, Substitution with Non-controlled Pain Medications and Tampering/Other Unauthorized Removals DYNALABS APPROACH DYNALABS works with hospitals to incorporate drug testing into their diversion protocols. This consists of a sampling program that randomly checks hospital personnel on selective drugs to assess drug alteration. In addition, DYNALABS can specifically focus on a particular drug, such as fentanyl, to monitor usage. DYNALABS LLC is registered with the U.S. Food and Drug Administration (FDA), DEA and Bureau of Narcotics and Dangerous Drugs licensed, as well as ISO 17025 accredited. The products and services provided by DYNALABS are protected by U.S. Patent Nos. 7,197,405 and 7,660,678. © 2018 DYNALABS LLC. All Rights Reserved. For spare information well-nigh DYNALABS please undeniability 888-396-2522 • info@dynalabs.usTerms Of Use • Privacy Policy • Customer Agreement